Approximately one-third of patients with non-small-cell lung cancer who were treated with the targeted therapy Lumakras (sotorasib) survived for at least two years after enrolling in a large clinical trial that evaluated the drug—significantly longer than what can be expected from patients treated with standard chemotherapy.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe